Since Clayton Hutson is a sound engineer, he knows there are things he can do that help bands sound better. He makes a point of giving them a chance to try different things and also does the best job he can at making everything work for himself and for other people who are a big part of the company. There are things that can give Clayton Hutson the chance to make the music industry better and he knew this when he started. For Clayton Hutson, the point of providing people with musical engineering is so their music sounds good no matter where they’re at or what they’re doing.
When bands like Halsey use Clayton Hutson as a sound engineer, they know they’re doing the right thing for their sound. They also know their fans love how they sound. Since people can hear the music better because of the sound engineer, they get more from the show they go to see. Halsey and Staind both knew this when they started doing work with Clayton Hutson. They also knew he was someone who could help them in different situations no matter what issues they had with sound in the past.
Sound engineers often work with people in the studio. Clayton Hutson knew this and also knew he could do more than just working in the studio. Instead of just helping produce the music while they’re making it, Clayton Hutson also helps artists by following them around to different venues. He shows them what they can get and how they can make sure they sound the best they can. He works with different artists to come up with new sounds so no artist sounds the same even if they’re at the same venue. He makes a point of showing people they can do more with the right music. Learn more: https://clayhutson.com/about-clay-hutson
While Clayton Hutson knows what he’s doing, he doesn’t try to produce the music. Instead, he lets the artists come up with all the music choices they have. He spends his time trying to show them that things will get better with his help, but he doesn’t want to make the actual music. For Clayton Hutson, enhancing the music is the best part of the job. He also likes showing people they can have a better sound if they use the sound engineering techniques he uses. It’s his goal of giving back to these artists that help him become better every time he helps someone.
Education and Career
Dr. Scott Rocklage holds a Bachelor of Science in Chemistry from the University of California. Dr. Rocklage joined the Massachusetts Institute of Technology (MIT) where he received a Ph.D. in Chemistry. He carried out his research while at Massachusetts Institute of Technology in Richard Schrock’s laboratory. Dr. Richard R. Schrock is a 2005 Nobel Peace Prize in Chemistry winner. In 2003, Dr. Scott Rocklage joined 5AM Ventures when he became the new Venture Partner. He became a Managing Partner a year later. Dr. Rocklage has accumulated over 30 years experience in the healthcare management. He is the one who gave the FDA approval for Omniscan, Cubicin, and Teslascan medications. He is a serial investor with over 30 U.S patents which he has either co-invented or invented.
Positions Previously Held
He was the C.E.O and Chairman of Cubist Pharmaceuticals. Dr. Rocklage was also the C.E.O and President of Nycomed Salutar. He also held many R&D positions in Catalytica. Dr. Scott Rocklage has served as the Chairperson of the Board of Directors for Novira, Relypsa, and Achaogen. At the moment he is the Board of Director Chairman for Rennovia, Cidara, and Kinestral. Dr. Rocklage has severed as a member of the Board of various companies, including those of Variation Biotechnologies, Epirus Biopharmaceuticals, WaveRX, Inc., and Pulmatrix. Dr. Rocklage has previously worked at Zalicus Inc. as an Independent Director. He currently works at 5AM Ventures.
Dr. Scott Rocklage issued a press release stating that Dr. Matthew Disney will be the one to lead Expansion Therapeutics research. These sentiments were echoed by Expansion Therapeutics chairman of the board and founding investor. Dr. Matthew Disney stated the work of over 12 years which he and his team have put together is what has led them to the position they are in today.
Expansion Therapeutics and Dr. Scott Rocklage have not only teamed up for the research, but they are also planning to advance small molecule medicine field that targets RNA. Beth Seidenberg, Kleiner Perkins’s General Partner said that she and her firm are happy to form a partnership with a company that is going to make it possible to treat illnesses that are currently incurable.
Expansion Therapeutics create medications that combat diseases that develop in the RNA. On the list of the firm’s concern diseases, is expansion repeat disorder. These are hereditary diseases and do not respond well to the available medication. Expansion repeat disorders have defective genes that are caused by repeats of small portions of DNA. Myotonic dystrophy type I (DM1) is one type of such diseases.
Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.